It was India that authorized the first nasal vaccine against Covid. It is, according to specialists, the tool that could put an end to the spread of the virus. Here because.
The Comptroller General of Medicines of India (DCGI) approved Bharat Biotech’s recombinant nasal vaccine against Covid-19 on Tuesday, September 6. This is the first worldwide authorization for this type of vaccine which represents a real hope for controlling the Covid-19 pandemic.
The company based in Hyderabad, in the center of the country, has conducted clinical studies on about 4,000 people but has not yet presented efficacy data. However, it ensures that no side effects or adverse effects have been reported so far.
At the same time, an inhaled booster dose was authorized in China.
Spray, the future of the fight against Covid-19?
Spray vaccines are the future of the fight against the coronavirus. And this for many reasons.
The main one seems to be simple and elementary, is that there is no better place to “inject” a product against a respiratory disease than through the nose or mouth. This was one of the limitations of intramuscularly injected vaccines. They reach their goal much less quickly. This has a significant impact on transmission even though they provide excellent protection against severe forms.
Around 100 oral or nasal vaccines are currently in development worldwide, of which around 20 have reached the human clinical trial stage. Specialists assure him that these solutions will quickly stop the virus before it spreads, as indicated by the medical journal Nature.
Vaccine developers hope their products will prevent even mild cases of the disease and block transmission to others, leading to sterilization of immunity.
These vaccines could be used both as a first dose and as a booster dose.
France recalls the rules on virucidal sprays
Faced with the imminent arrival on the market of these oral or nasal vaccines, the French Medicines Agency published a notice, this Wednesday 7 September, to the attention of companies that would be called to market them.
It therefore invites them to “abide by the rules before any sale of these nasal sprays” on both qualification and classification as well as clinical data and claims in order not to mislead the user regarding the indication, safety and performance of the device. In particular, on an action against Covid-19 which cannot be claimed if the performance of the nasal spray has not been demonstrated.